New Ray Medicine International Holding (HKG:6108) recorded a loss attributable to owners of HK$4.09 million for the six months ended June 30, narrower than HK$13.4 million logged for the corresponding period last year, a Tuesday filing with the Hong Kong Exchange said.
Loss per share stood at HK$0.0024 for the reporting period, compared to HK$0.0080 recorded for the year-ago period.
The investment and pharmaceutical company's revenue for the first half of this year was HK$16.7 million, 46.1% lower than HK$31.0 million booked a year ago. The company attributed the decrease in revenue to a decrease in demand for its products in the market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.